Page last updated: 2024-08-16

temozolomide and stattic

temozolomide has been researched along with stattic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Cortes, U; Dkhissi, F; Dusanter-Fourt, I; Karayan-Tapon, L; Le Corf, A; Martin-Lannerée, S; Tourani, JM; Turhan, AG; Villalva, C; Wager, M1
Chen, Y; Guan, Q; Guo, Y; Ji, G; Jin, Y; Li, C; Liu, P; Ma, Y; Mu, Y; Sun, D; Sun, H; Wu, N; Xu, Y; Zhang, Y; Zhao, M; Zhou, C1

Other Studies

2 other study(ies) available for temozolomide and stattic

ArticleYear
STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?
    International journal of cancer, 2011, Feb-15, Volume: 128, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Cyclic S-Oxides; Dacarbazine; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Neural Stem Cells; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; STAT3 Transcription Factor; Temozolomide; Tumor Cells, Cultured

2011
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
    Cell death & disease, 2023, Nov-20, Volume: 14, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Oncogenes; Ribosomal Proteins; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays

2023